RAD51 as a candidate parathyroid tumour suppressor gene on chromosome 15q:: absence of somatic mutations

被引:9
作者
Carling, T
Imanishi, Y
Gaz, RD
Arnold, A
机构
[1] Univ Connecticut, Sch Med, Ctr Mol Med, Farmington, CT 06030 USA
[2] Univ Connecticut, Sch Med, Div Endocrinol & Metab, Farmington, CT 06030 USA
[3] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA
关键词
D O I
10.1046/j.1365-2265.1999.00779.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Loss of heterozygosity (LOH) at chromosome 15q is frequent in parathyroid adenomas, but no tumour suppressor gene of importance to parathyroid tumour development has been isolated from this region. The RAD51 gene has been localized to chromosome 15q and possesses regulatory functions involving DNA stability and cell proliferation, suggesting its possible role in tumorigenesis, Additionally, mutations in the RAD51 gene cause reduced resistance to ionizing radiation, which is a major risk factor for primary hyperparathyroidism, RAD51 was therefore analysed as a candidate tumour suppressor gene in a group of parathyroid adenomas for which mutations in a 15q tumour suppressor should be most readily detectable. PATIENTS AND DESIGN From a total of 55 parathyroid adenomas, nine were selected based on their LOH pattern showing DNA loss at chromosome 15q in the vicinity of the RAD51 gene. RAD51 mRNA expression was investigated by reverse transcription-polymerase chain reaction (RT-PCR), and sequence analysis of the entire coding region of the RAD51 cDNA was performed in all nine adenomas. RESULTS RAD51 mRNA expression was substantiated in all parathyroid adenomas, Compared with the normal RAD51 cDNA sequence, no point mutations or microdeletions could be found in the parathyroid tumor cDNA, CONCLUSION These observations suggest that somatic inactivating mutations of the RAD51 gene are uncommonly, if ever, associated with parathyroid tumourigenesis.
引用
收藏
页码:403 / 407
页数:5
相关论文
共 41 条
[1]  
Arnold Andrew, 1994, P407
[2]   Double indemnity: p53, BRCA and cancer [J].
Brugarolas, J ;
Jacks, T .
NATURE MEDICINE, 1997, 3 (07) :721-722
[3]   Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism [J].
Carling, T ;
Correa, P ;
Hessman, O ;
Hedberg, J ;
Skogseid, B ;
Lindberg, D ;
Rastad, J ;
Westin, G ;
Åkerström, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (08) :2960-2963
[4]   Positional cloning of the gene for multiple endocrine neoplasia-type 1 [J].
Chandrasekharappa, SC ;
Guru, SC ;
Manickam, P ;
Olufemi, SE ;
Collins, FS ;
EmmertBuck, MR ;
Debelenko, LV ;
Zhuang, ZP ;
Lubensky, IA ;
Liotta, LA ;
Crabtree, JS ;
Wang, YP ;
Roe, BA ;
Weisemann, J ;
Boguski, MS ;
Agarwal, SK ;
Kester, MB ;
Kim, YS ;
Heppner, C ;
Dong, QH ;
Spiegel, AM ;
Burns, AL ;
Marx, SJ .
SCIENCE, 1997, 276 (5311) :404-407
[5]   Chromosomal rearrangements occur in S-cerevisiae rfa1 mutator mutants due to mutagenic lesions processed by double-strand-break repair [J].
Chen, C ;
Umezu, K ;
Kolodner, RD .
MOLECULAR CELL, 1998, 2 (01) :9-22
[6]  
CLIBY W, 1993, CANCER RES, V53, P2393
[7]  
COHEN J, 1990, JAMA-J AM MED ASSOC, V264, P581
[8]   FREQUENT LOSS OF CHROMOSOME ARM IP DNA IN PARATHYROID ADENOMAS [J].
CRYNS, VL ;
YI, SM ;
TAHARA, H ;
GAZ, RD ;
ARNOLD, A .
GENES CHROMOSOMES & CANCER, 1995, 13 (01) :9-17
[9]  
DEVILEE P, 1991, ONCOGENE, V6, P1705
[10]   Differential loss of heterozygosity in familial, sporadic, and uremic hyperparathyroidism [J].
Farnebo, F ;
Teh, BT ;
Dotzenrath, C ;
Wassif, WS ;
Svensson, A ;
White, I ;
Betz, R ;
Goretzki, P ;
Sandelin, K ;
Farnebo, LO ;
Larsson, C .
HUMAN GENETICS, 1997, 99 (03) :342-349